Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

September 12, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person * **GOLDBERG MURRAY A**

2. Issuer Name and Ticker or Trading

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

Symbol

REGENERON

PHARMACEUTICALS INC

[REGN]

(Last) (First) (Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 09/08/2011

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

Director

10% Owner X_ Officer (give title Other (specify below)

SVP Finance and Admin CFO Trea

777 OLD SAW MILL RIVER ROAD

(Street)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

TARRYTOWN, NY 10591

(City)	(State)	(Zip) Tabl	le I - Non-D	Derivative S	Securi	ties Acqu	ired, Disposed of	f, or Beneficiall	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and 5)			5. Amount of Securities Ownership Beneficially Form: Direct Owned (D) or Following Indirect (I) Reported (Instr. 4) Transaction(s)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	09/08/2011		M <u>(1)</u>	26,000	A	\$ 11.64	103,734	D	
Common Stock	09/08/2011		F(1)	4,168	D	\$ 72.6	99,566	D	
Common Stock	09/08/2011		F <u>(1)</u>	10,090	D	\$ 72.6	89,476	D	
Common Stock	09/09/2011		S(1)	3,942	D	\$ 67.19 (2)	85,534	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock	09/09/2011	S <u>(1)</u>	3,400	D	\$ 68.45 (3)	82,134	D	
Common Stock	09/09/2011	S <u>(1)</u>	200	D	\$ 69.08 (4)	81,934	D	
Common Stock						5,416	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and A Underlying S (Instr. 3 and	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 11.64	09/08/2011		M <u>(1)</u>		26,000	<u>(5)</u>	12/19/2015	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 72.6	09/08/2011		A <u>(1)</u>	4,168		09/08/2011	12/19/2015	Common Stock

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

GOLDBERG MURRAY A 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

SVP Finance and Admin CFO Trea

Signatures

/s/**Murray A. 09/12/2011 Goldberg

Date

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 3,942 shares of Company stock on September 9, 2011 at prices ranging from (2) \$67.00 to \$67.92 Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the trust on September 9, 2011 at each separate price.
- Represents volume-weighted average price of sales of 3,400 shares of Company stock on September 9, 2011 at prices ranging from (3) \$68.01 to \$68.93 Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the trust on September 9, 2011 at each separate price
- Represents volume-weighted average price of sales of 200 shares of Company stock on September 9, 2011 at prices ranging from \$69.04 (4) to \$69.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the trust on September 9, 2011 at each separate price.
- (5) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (6) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3